The Prime Study is an in-development project.
- The logo will be used primarily for the purposes of promotion and dissemination of study findings. It will be used on the website of the study's coordinating organisation, the Burnet Institute (http://www.burnet.edu.au), and on dissemination products (e.g., PowerPoint presentations at conferences, the study's final report).
- The target audience will be key professional stakeholders in public health (e.g., government representatives, fellow researchers, staff of health services, such as hospitals).
Background to the Prime Study:
- Hepatitis C Virus is a major global cause of liver cirrhosis and cancer. Transmission occurs primarily through blood contact.
- In a number of developed countries, including Australia, injecting drugs with non-clean equipment is the most common form of Hepatitis C transmission.
- Unfortunately, there is no vaccine for the virus. In addition, current treatments are not 100% effective and are generally associated with numerous negative side-effects. Treatment is available only through large tertiary hospitals. Multiple barriers to accessing care results in less than 2% of the infected Australian population being treated each year.
- However, research trials have demonstrated that a new drug can safely and effectively treat Hepatitis C.
- The Prime Study will investigate the feasibility of treating people infected with Hepatitis C using this new therapy in primary health care centres, in comparison to standard of care therapy in large tertiary hospitals.
- Providing care in the primary healthcare setting may significantly increase treatment accessibility, and therefore the number of people treated and cured.